• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Brain Behav . De Novo Immune Induction After COVID-19 Vaccination Under B-Cell Depletion Is Characterized by Robust T-Cellular Immunity in Patients

tetano

Editor, Senior Moderator
Brain Behav


. 2025 Sep;15(9):e70849.
doi: 10.1002/brb3.70849. De Novo Immune Induction After COVID-19 Vaccination Under B-Cell Depletion Is Characterized by Robust T-Cellular Immunity in Patients With Inflammatory Central Nervous System Disease

Mathias Fousse[SUP] 1 [/SUP], Verena Klemis[SUP] 2 [/SUP], Saskia Bronder[SUP] 2 [/SUP], Rebecca Urschel[SUP] 2 [/SUP], Franziska Hielscher[SUP] 2 [/SUP], Klaus Faßbender[SUP] 1 [/SUP], Urban Sester[SUP] 3 [/SUP], Martina Sester[SUP] 2 [/SUP], Tina Schmidt[SUP] 2 [/SUP]



Affiliations
Abstract

Background: Immune induction under B-cell depletion is complex and far from being fully understood.
Methods: We investigated clinical and immunological responses after dual homologous mRNA vaccination with BNT162b2 and after booster vaccination or infection in 14 B-cell depleted patients with inflammatory central nervous system disease in comparison to 28 healthy controls. Spike-specific IgG were determined using ELISA and neutralizing activity by surrogate assay. Reactive T cells were flow-cytometrically analyzed after spike-specific and polyclonal stimulation. Reactogenicity was self-reported using a questionnaire.
Results: Vaccination was well tolerated, with slightly more systemic events reported by patients. Spike-specific antibodies were induced in all controls, but only 43% of patients with significantly lower IgG levels and reduced neutralizing capacity (p < 0.0001). In contrast, spike-reactive T cells were induced in both groups with similar CD4 and higher CD8 T-cell levels in patients. Functional characterization of spike-reactive T cells revealed equally high CTLA-4 expression in both groups, but higher proportions of polyfunctional, triple-cytokine expressing CD4 and CD8 T cells in patients especially after the third immunization. Three patients experienced mild breakthrough infections after second vaccination.
Conclusions: Despite limited ability of B-cell depleted patients to mount a humoral immune response after multiple doses of SARS-CoV-2 mRNA vaccination, the vaccine-induced T-cell response is robust, which may have implications for protection against severe disease.

Keywords: B‐cell depletion; SARS‐CoV‐2; T cells; multiple sclerosis; vaccination.

 
Back
Top Bottom